NRx Pharmaceuticals Q1 2026 Earnings Report

NRx Pharmaceuticals EPS Results

• Actual EPS: -$0.04
• Consensus EPS: -$0.05
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

NRx Pharmaceuticals Revenue Results

• Actual Revenue: $1.07 million
• Expected Revenue: $19.43 million
• Beat/Miss: Missed by -$18.36 million
• YoY Revenue Growth: N/A

NRx Pharmaceuticals Announcement Details

• Quarter: Q1 2026
• Date: 5/18/2026
• Time: Before Market Opens
• Conference Call Date: Monday, May 18, 2026
• Conference Call Time: 8:00AM ET

NRx Pharmaceuticals (NASDAQ:NRXP) is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications. The company’s development programs are designed to address high-unmet-need patient populations, applying precision-medicine principles to optimize dosing regimens and patient selection. By building on decades of prior clinical experience with these molecules, NRx aims to reduce development timelines and costs relative to novel drug discovery.

Headquartered in New York, NRx Pharmaceuticals operates a lean corporate structure, with R&D activities supported by a network of external partners and contract research organizations. The company is led by a management team with deep expertise in pharmaceutical development, regulatory affairs and commercial strategy, drawing on experience at major biotech and global healthcare companies. Through strategic collaborations and disciplined capital allocation, NRx seeks to advance its product candidates efficiently toward regulatory milestones and, ultimately, market approval.